MannKind (MNKD) Competitors

MannKind logo
$4.07 +0.12 (+3.04%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$4.12 +0.04 (+1.11%)
As of 11/17/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MNKD vs. TVTX, CRSP, DNTH, CDNA, and LEGN

Should you buy MannKind stock or one of its competitors? MannKind's main competitors and comparable companies include Travere Therapeutics (TVTX), CRISPR Therapeutics (CRSP), Dianthus Therapeutics (DNTH), CareDx (CDNA), and Legend Biotech (LEGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MannKind compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and MannKind (NASDAQ:MNKD) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Travere Therapeutics presently has a consensus target price of $72.55, suggesting a potential upside of 41.97%. MannKind has a consensus target price of $8.50, suggesting a potential upside of 108.85%. Given MannKind's higher possible upside, analysts clearly believe MannKind is more favorable than Travere Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Travere Therapeutics
2 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.69
MannKind
1 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.60

In the previous week, MannKind had 2 more articles in the media than Travere Therapeutics. MarketBeat recorded 5 mentions for MannKind and 3 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.32 beat MannKind's score of 0.38 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Travere Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
MannKind
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

49.6% of MannKind shares are held by institutional investors. 4.4% of Travere Therapeutics shares are held by insiders. Comparatively, 2.6% of MannKind shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

MannKind has lower revenue, but higher earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Travere Therapeutics$490.73M10.00-$25.55M-$1.29N/A
MannKind$348.97M3.75$5.86M-$0.23N/A

Travere Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, MannKind has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market.

MannKind has a net margin of -18.10% compared to Travere Therapeutics' net margin of -18.66%. MannKind's return on equity of 0.00% beat Travere Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Travere Therapeutics-18.66% -185.69% -17.24%
MannKind -18.10%N/A -10.01%

Summary

MannKind beats Travere Therapeutics on 9 of the 16 factors compared between the two stocks.

How does MannKind compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and MannKind (NASDAQ:MNKD) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

In the previous week, CRISPR Therapeutics had 4 more articles in the media than MannKind. MarketBeat recorded 9 mentions for CRISPR Therapeutics and 5 mentions for MannKind. MannKind's average media sentiment score of 0.38 beat CRISPR Therapeutics' score of 0.32 indicating that MannKind is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CRISPR Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral
MannKind
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by insiders. Comparatively, 2.6% of MannKind shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

MannKind has higher revenue and earnings than CRISPR Therapeutics. MannKind is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISPR Therapeutics$3.51M1,109.56-$581.60M-$4.74N/A
MannKind$348.97M3.75$5.86M-$0.23N/A

CRISPR Therapeutics has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market. Comparatively, MannKind has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

CRISPR Therapeutics currently has a consensus price target of $72.93, suggesting a potential upside of 81.64%. MannKind has a consensus price target of $8.50, suggesting a potential upside of 108.85%. Given MannKind's higher probable upside, analysts plainly believe MannKind is more favorable than CRISPR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CRISPR Therapeutics
1 Sell rating(s)
6 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.65
MannKind
1 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.60

MannKind has a net margin of -18.10% compared to CRISPR Therapeutics' net margin of -1,812.07%. MannKind's return on equity of 0.00% beat CRISPR Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISPR Therapeutics-1,812.07% -25.59% -17.89%
MannKind -18.10%N/A -10.01%

Summary

CRISPR Therapeutics and MannKind tied by winning 8 of the 16 factors compared between the two stocks.

How does MannKind compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and MannKind (NASDAQ:MNKD) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

MannKind has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dianthus Therapeutics$2.04M2,400.90-$162.34M-$3.99N/A
MannKind$348.97M3.75$5.86M-$0.23N/A

Dianthus Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market. Comparatively, MannKind has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by insiders. Comparatively, 2.6% of MannKind shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

MannKind has a net margin of -18.10% compared to Dianthus Therapeutics' net margin of -7,436.50%. MannKind's return on equity of 0.00% beat Dianthus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Dianthus Therapeutics-7,436.50% -19.68% -18.95%
MannKind -18.10%N/A -10.01%

In the previous week, Dianthus Therapeutics had 11 more articles in the media than MannKind. MarketBeat recorded 16 mentions for Dianthus Therapeutics and 5 mentions for MannKind. Dianthus Therapeutics' average media sentiment score of 0.51 beat MannKind's score of 0.38 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dianthus Therapeutics
6 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
MannKind
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Dianthus Therapeutics presently has a consensus price target of $128.77, suggesting a potential upside of 48.04%. MannKind has a consensus price target of $8.50, suggesting a potential upside of 108.85%. Given MannKind's higher possible upside, analysts clearly believe MannKind is more favorable than Dianthus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dianthus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
3.00
MannKind
1 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.60

Summary

MannKind beats Dianthus Therapeutics on 9 of the 17 factors compared between the two stocks.

How does MannKind compare to CareDx?

MannKind (NASDAQ:MNKD) and CareDx (NASDAQ:CDNA) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

CareDx has a net margin of 25.86% compared to MannKind's net margin of -18.10%. CareDx's return on equity of 9.74% beat MannKind's return on equity.

Company Net Margins Return on Equity Return on Assets
MannKind-18.10% N/A -10.01%
CareDx 25.86%9.74%7.35%

MannKind has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, CareDx has a beta of 2.51, meaning that its share price is 151% more volatile than the broader market.

In the previous week, CareDx had 9 more articles in the media than MannKind. MarketBeat recorded 14 mentions for CareDx and 5 mentions for MannKind. CareDx's average media sentiment score of 0.60 beat MannKind's score of 0.38 indicating that CareDx is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MannKind
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
CareDx
6 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

49.6% of MannKind shares are owned by institutional investors. 2.6% of MannKind shares are owned by company insiders. Comparatively, 2.4% of CareDx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

MannKind presently has a consensus price target of $8.50, suggesting a potential upside of 108.85%. CareDx has a consensus price target of $70.33, suggesting a potential downside of 5.67%. Given MannKind's higher probable upside, equities analysts clearly believe MannKind is more favorable than CareDx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MannKind
1 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.60
CareDx
0 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.67

MannKind has higher earnings, but lower revenue than CareDx. MannKind is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MannKind$348.97M3.75$5.86M-$0.23N/A
CareDx$379.80M10.31-$21.35M$2.3931.20

Summary

CareDx beats MannKind on 12 of the 17 factors compared between the two stocks.

How does MannKind compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and MannKind (NASDAQ:MNKD) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 49.6% of MannKind shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by company insiders. Comparatively, 2.6% of MannKind shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Legend Biotech presently has a consensus target price of $48.64, indicating a potential upside of 201.94%. MannKind has a consensus target price of $8.50, indicating a potential upside of 108.85%. Given Legend Biotech's higher possible upside, equities analysts clearly believe Legend Biotech is more favorable than MannKind.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Legend Biotech
1 Sell rating(s)
6 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.50
MannKind
1 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.60

Legend Biotech has a net margin of -0.02% compared to MannKind's net margin of -18.10%. MannKind's return on equity of 0.00% beat Legend Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Legend Biotech-0.02% -0.03% -0.02%
MannKind -18.10%N/A -10.01%

In the previous week, Legend Biotech had 22 more articles in the media than MannKind. MarketBeat recorded 27 mentions for Legend Biotech and 5 mentions for MannKind. MannKind's average media sentiment score of 0.38 beat Legend Biotech's score of -0.12 indicating that MannKind is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Legend Biotech
1 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
10 Negative mention(s)
1 Very Negative mention(s)
Neutral
MannKind
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Legend Biotech has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, MannKind has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

MannKind has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Legend Biotech$1.03B3.04-$296.80M-$0.01N/A
MannKind$348.97M3.75$5.86M-$0.23N/A

Summary

Legend Biotech beats MannKind on 8 of the 15 factors compared between the two stocks.

Get MannKind News Delivered to You Automatically

Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MNKD vs. The Competition

MetricMannKindBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.27B$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E Ratio-17.7026.0433.0226.92
Price / Sales3.7516.068.565.70
Price / Cash63.9222.9521.0121.90
Price / Book-33.924.184.463.72
Net Income$5.86M-$24.15M$3.52B$393.10M
7 Day Performance-2.86%-7.80%-5.94%-5.76%
1 Month Performance33.88%-5.98%-4.59%-7.14%
1 Year Performance-19.57%-8.10%-1.94%-7.46%

MannKind Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MNKD
MannKind
2.3967 of 5 stars
$4.07
+3.0%
$8.50
+108.8%
-18.3%$1.27B$348.97MN/A592
TVTX
Travere Therapeutics
3.6921 of 5 stars
$51.63
+4.1%
$72.55
+40.5%
+44.2%$5.03B$490.73MN/A497
CRSP
CRISPR Therapeutics
2.6385 of 5 stars
$50.04
-0.1%
$69.69
+39.3%
-27.4%$5.02B$3.51MN/A393
DNTH
Dianthus Therapeutics
2.233 of 5 stars
$90.00
+4.6%
$128.77
+43.1%
+110.4%$4.70B$2.04MN/A92
CDNA
CareDx
1.1971 of 5 stars
$84.42
+7.5%
$64.40
-23.7%
+380.7%$4.51B$379.80M130.09765

Related Companies and Tools


This page (NASDAQ:MNKD) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners